| Year |
Citation |
Score |
| 2024 |
Gómez Tejeda Zañudo J, Barroso-Sousa R, Jain E, Jin Q, Li T, Buendia-Buendia JE, Pereslete A, Abravanel DL, Ferreira AR, Wrabel E, Helvie K, Hughes ME, Partridge AH, Overmoyer B, Lin NU, ... ... Wagle N, et al. Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nature Communications. 15: 2446. PMID 38503755 DOI: 10.1038/s41467-024-45835-6 |
0.376 |
|
| 2023 |
Fu X, Pereira R, Liu CC, De Angelis C, Shea MJ, Nanda S, Qin L, Mitchell T, Cataldo ML, Veeraraghavan J, Sethunath V, Giuliano M, Gutierrez C, Győrffy B, Trivedi MV, ... ... Wagle N, et al. High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer. Cell Reports. 42: 112821. PMID 37467106 DOI: 10.1016/j.celrep.2023.112821 |
0.314 |
|
| 2023 |
Brett JO, Dubash TD, Johnson GN, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Lloyd MR, Kambadakone A, Spring LM, Micalizzi DS, Onozato ML, ... ... Wagle N, et al. A Gene Panel Associated With Abemaciclib Utility in -Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. Jco Precision Oncology. 7: e2200532. PMID 37141550 DOI: 10.1200/PO.22.00532 |
0.677 |
|
| 2022 |
Crowdis J, Balch S, Sterlin L, Thomas BS, Camp SY, Dunphy M, Anastasio E, Shah S, Damon AL, Ramos R, Sosa DM, Small IK, Tomson BN, Nguyen CM, McGillicuddy M, ... ... Wagle N, et al. A patient-driven clinicogenomic partnership for metastatic prostate cancer. Cell Genomics. 2. PMID 36177448 DOI: 10.1016/j.xgen.2022.100169 |
0.567 |
|
| 2022 |
Barroso-Sousa R, Forman J, Collier K, Weber ZT, Jammihal TR, Kao KZ, Richardson ET, Keenan T, Cohen O, Manos MP, Brennick RC, Ott PA, Hodi FS, Dillon DA, Attaya V, ... ... Wagle N, et al. Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. Jco Precision Oncology. 6: e2100413. PMID 35797509 DOI: 10.1200/PO.21.00413 |
0.57 |
|
| 2022 |
Li Z, McGinn O, Wu Y, Bahreini A, Priedigkeit NM, Ding K, Onkar S, Lampenfeld C, Sartorius CA, Miller L, Rosenzweig M, Cohen O, Wagle N, Richer JK, Muller WJ, et al. ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. Nature Communications. 13: 2011. PMID 35440136 DOI: 10.1038/s41467-022-29498-9 |
0.35 |
|
| 2022 |
Li Z, Wu Y, Yates ME, Tasdemir N, Bahreini A, Chen J, Levine KM, Priedigkeit NM, Nasrazadani A, Ali S, Buluwela L, Arnesen S, Gertz J, Richer JK, Troness B, ... ... Wagle N, et al. Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis. Cancer Research. PMID 35078818 DOI: 10.1158/0008-5472.CAN-21-2576 |
0.39 |
|
| 2021 |
Qi M, Nayar U, Ludwig LS, Wagle N, Rheinbay E. cDNA-detector: detection and removal of cDNA contamination in DNA sequencing libraries. Bmc Bioinformatics. 22: 611. PMID 34952565 DOI: 10.1186/s12859-021-04529-2 |
0.576 |
|
| 2021 |
Alcon C, Gómez Tejeda Zañudo J, Albert R, Wagle N, Scaltriti M, Letai A, Samitier J, Montero J. ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins. Cells. 10. PMID 34359829 DOI: 10.3390/cells10071659 |
0.326 |
|
| 2021 |
Balch SM, Vaz-Luis I, Li T, Tayob N, Jain E, Helvie K, Buendia-Buendia JE, Shannon E, Isakoff SJ, Tung NM, Krop IE, Lin NU, Wagle N, Freedman RA. A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. Breast Cancer Research and Treatment. PMID 34302589 DOI: 10.1007/s10549-021-06329-x |
0.305 |
|
| 2021 |
Gómez Tejeda Zañudo J, Mao P, Alcon C, Kowalski K, Johnson GN, Xu G, Baselga J, Scaltriti M, Letai A, Montero J, Albert R, Wagle N. Cell line-specific network models of ER+ breast cancer identify potential PI3Kα inhibitor resistance mechanisms and drug combinations. Cancer Research. PMID 34257082 DOI: 10.1158/0008-5472.CAN-21-1208 |
0.301 |
|
| 2021 |
Wander SA, Han HS, Zangardi ML, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Kambadakone A, Stein C, Lloyd MR, Yuen M, Spring LM, ... ... Wagle N, et al. Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. Journal of the National Comprehensive Cancer Network : Jnccn. 1-8. PMID 33761455 DOI: 10.6004/jnccn.2020.7662 |
0.312 |
|
| 2020 |
Garrido-Castro AC, Spurr LF, Hughes ME, Li YY, Cherniack AD, Kumari P, Lloyd MR, Bychkovsky B, Barroso-Sousa R, Di Lascio S, Jain E, Files JL, Mohammed-Abreu A, Krevalin M, MacKichan C, ... ... Wagle N, et al. Genomic characterization of de novo metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33293374 DOI: 10.1158/1078-0432.CCR-20-1720 |
0.305 |
|
| 2020 |
Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32853681 DOI: 10.1016/J.Annonc.2020.07.014 |
0.452 |
|
| 2020 |
Mao P, Cohen O, Kowalski KJ, Kusiel J, Buendia-Buendia JE, Cuoco MS, Exman P, Wander SA, Waks AG, Nayar U, Chung JH, Freeman SS, Rozenblatt-Rosen O, Miller VA, Piccioni F, ... ... Wagle N, et al. Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32723837 DOI: 10.1158/1078-0432.Ccr-19-3958 |
0.67 |
|
| 2020 |
Slyper M, Porter CBM, Ashenberg O, Waldman J, Drokhlyansky E, Wakiro I, Smillie C, Smith-Rosario G, Wu J, Dionne D, Vigneau S, Jané-Valbuena J, Tickle TL, Napolitano S, Su MJ, ... ... Wagle N, et al. A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nature Medicine. 26: 792-802. PMID 32405060 DOI: 10.1038/S41591-020-0844-1 |
0.37 |
|
| 2020 |
Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, Kim D, Luo F, Mao P, Helvie K, Kowalski KJ, Nayar U, Waks AG, Parsons SH, Martinez R, ... ... Wagle N, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer. Cancer Discovery. PMID 32404308 DOI: 10.1158/2159-8290.Cd-19-1390 |
0.766 |
|
| 2020 |
Cooper AJ, Kobayashi Y, Kim D, Clifford SE, Kravets S, Dahlberg SE, Chambers ES, Li J, Rangachari D, Nguyen T, Costa DB, Rabin MS, Wagle N, Sholl LM, Janne PA, et al. Identification of a RAS-activating TMEM87A-RASGRF1 fusion in an exceptional responder to sunitinib with non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32312893 DOI: 10.1158/1078-0432.Ccr-20-0397 |
0.356 |
|
| 2020 |
Waks AG, Cohen O, Kochupurakkal B, Kim D, Dunn CE, Buendia Buendia J, Wander S, Helvie K, Lloyd MR, Marini L, Hughes ME, Freeman SS, Ivy SP, Geradts J, Isakoff S, ... ... Wagle N, et al. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32245699 DOI: 10.1016/J.Annonc.2020.02.008 |
0.478 |
|
| 2020 |
Parsons HA, Rhoades J, Reed SC, Gydush G, Ram P, Exman P, Xiong K, Lo CC, Li T, Fleharty M, Kirkner GJ, Rotem D, Cohen O, Yu F, Fitarelli-Kiehl M, ... ... Wagle N, et al. Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32170028 DOI: 10.1158/1078-0432.Ccr-19-3005 |
0.392 |
|
| 2020 |
Barroso-Sousa R, Jain E, Cohen O, Kim D, Buendia-Buendia J, Winer E, Lin N, Tolaney SM, Wagle N. Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 31: 387-394. PMID 32067680 DOI: 10.1016/J.Annonc.2019.11.010 |
0.488 |
|
| 2020 |
Painter CA, Jain E, Tomson BN, Dunphy M, Stoddard RE, Thomas BS, Damon AL, Shah S, Kim D, Gómez Tejeda Zañudo J, Hornick JL, Chen YL, Merriam P, Raut CP, Demetri GD, ... ... Wagle N, et al. The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nature Medicine. PMID 32042194 DOI: 10.1038/S41591-019-0749-Z |
0.507 |
|
| 2020 |
Barroso-Sousa R, Keenan TE, Pernas S, Exman P, Jain E, Garrido-Castro AC, Hughes ME, Bychkovsky B, Umeton R, Files JL, Lindeman NI, MacConaill LE, Hodi FS, Krop I, Dillon DA, ... ... Wagle N, et al. Tumor mutational burden and alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32019858 DOI: 10.1158/1078-0432.Ccr-19-3507 |
0.653 |
|
| 2020 |
Wagle N, Painter C, Anastasio E, Dunphy M, McGillicuddy M, Jain E, Hernandez TG, Balch S, Thomas B, Kim D, Damon AL, Shah S, Tomson BN, Stoddard R, Nguyen C, et al. Abstract PD8-01: The metastatic breast cancer project: Generating the clinical and genomic landscape of metastatic breast cancer through patient-partnered research Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd8-01 |
0.487 |
|
| 2020 |
Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia J, Lloyd M, Kim D, Luo F, Mao P, Helvie K, Kowalski K, Nayar U, Parsons S, Martinez R, Litchfield L, ... Wagle N, et al. Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC) Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd2-09 |
0.648 |
|
| 2020 |
Wander S, Mao P, Lloyd M, Kowalski K, Johnson GN, Malvarosa G, Moy B, Ellisen LW, Iafrate J, Wagle N, Bardia A. Abstract P6-10-08: AKT1 alterations following exposure to endocrine-based therapy in patients with hormone-receptor positive (HR+) metastatic breast cancer (MBC): Clinical and functional implications Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-10-08 |
0.551 |
|
| 2020 |
Fu X, Pereira R, Angelis CD, Nanda S, Qin L, Shea MJ, Mitchell T, Veeraraghavan J, Sethunath V, Gutierrez C, Győrffy B, Cohen O, Wagle N, Nardone A, Jeselsohn R, et al. Abstract P6-04-02: Integrative cistromic/transcriptomic profiling identifies a high FOXA1/ER-activated pro-metastatic secretome in endocrine-resistant breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-04-02 |
0.407 |
|
| 2020 |
Barroso-Sousa R, Li T, Trippa L, Rees R, Andrews C, Ferreira AR, Helvie K, Partridge AH, Overmoyer B, Winer EP, Wagle N, Tolaney SM. Abstract P5-11-04: A phase I/IIb study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): Results of the phase II study Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P5-11-04 |
0.464 |
|
| 2020 |
Parsons HA, Rhoades J, Reed SC, Gydush G, Ram P, Exman P, Xiong K, Lo C, Li T, Fleharty M, Kirkner G, Rotem D, Cohen O, Hughes M, Rosenberg S, ... ... Wagle N, et al. Abstract P5-01-03: Ultrasensitive detection of minimal residual disease in patients treated for breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P5-01-03 |
0.456 |
|
| 2020 |
Buendia-Buendia JE, Pernas S, Cohen O, Mao PP, Kowalski K, Lin N, Winer E, Wagle N. Abstract P3-01-09: Clonal heterogeneity and tumor evolution inform treatment resistance in a patient with HER2+ breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P3-01-09 |
0.458 |
|
| 2020 |
Cohen O, Abravanel D, Slyper M, Klughammer J, Jane-Valbuena J, Helvie K, Dellostritto L, Frangieh A, Vigneau S, Wu J, Mayorga A, Waldman J, Nguyen L, Dionne D, Ashenberg O, ... ... Wagle N, et al. Abstract GS6-05: A joint atlas of single-cell and bulk RNA-seq in metastatic breast cancer allows inference of oncogenic and drug-resistant transcriptional programs in malignant cells and the tumor microenvironment Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs6-05 |
0.467 |
|
| 2020 |
Cohen O, Mao P, Nayar U, Buendia-Bue JE, Kim D, Jain E, Helvie K, Abravanel D, Kowalski KJ, Kapstad C, Freeman S, Adalsteinsson V, Wander SA, Waks AG, Getz G, ... ... Wagle N, et al. Abstract GS2-02: Acquired activating mutations in RTKs confer endocrine resistance in ER+ metastatic breast cancer through ER-reprogramming, MAPK signaling, and an induced stem-like cell state Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs2-02 |
0.463 |
|
| 2020 |
Nayar U, Piccioni F, Yang X, Root D, Neal JT, Eli LD, Diala I, Lalani AS, Wagle N. Abstract 1914: Phenotypic characterization of a comprehensive set of HER2 missense mutants in ER+ breast cancer Cancer Research. 80: 1914-1914. DOI: 10.1158/1538-7445.Am2020-1914 |
0.516 |
|
| 2019 |
Exman P, Garrido-Castro AC, Hughes ME, Freedman RA, Li T, Trippa L, Bychkovsky BL, Barroso-Sousa R, Di Lascio S, Mackichan C, Lloyd MR, Krevalin M, Cerami E, Merrill MS, Santiago R, ... ... Wagle N, et al. Identifying Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. Jco Precision Oncology. 3. PMID 32923853 DOI: 10.1200/PO.19.00087 |
0.368 |
|
| 2019 |
Fu X, Pereira R, De Angelis C, Veeraraghavan J, Nanda S, Qin L, Cataldo ML, Sethunath V, Mehravaran S, Gutierrez C, Chamness GC, Feng Q, O'Malley BW, Selenica P, Weigelt B, ... ... Wagle N, et al. FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 31826955 DOI: 10.1073/Pnas.1911584116 |
0.439 |
|
| 2019 |
Janiszewska M, Tabassum DP, Castaño Z, Cristea S, Yamamoto KN, Kingston NL, Murphy KC, Shu S, Harper NW, Del Alcazar CG, Alečković M, Ekram MB, Cohen O, Kwak M, Qin Y, ... ... Wagle N, et al. Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments. Nature Cell Biology. 21: 879-888. PMID 31263265 DOI: 10.1038/S41556-019-0346-X |
0.307 |
|
| 2019 |
Cornell L, Wander SA, Visal T, Wagle N, Shapiro GI. MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance. Cell Reports. 26: 2667-2680.e7. PMID 30840889 DOI: 10.1016/J.Celrep.2019.02.023 |
0.411 |
|
| 2019 |
Waks AG, Jain E, Collins LC, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, Come SE, Peppercorn JM, Borges VF, Warner E, Snow C, Partridge AH, Wagle N. Genomics of HER2+ breast cancer in young women before and after exposure to chemotherapy (chemo) plus trastuzumab (H). Journal of Clinical Oncology. 37: 554-554. DOI: 10.1200/Jco.2019.37.15_Suppl.554 |
0.41 |
|
| 2019 |
Waks AG, Cohen O, Kochupurakkal B, Kim D, Wander SA, Buendia-Buendia J, Helvie K, Matulonis UA, Krop IE, Tolaney SM, Winer EP, D'Andrea AD, Shapiro G, Lin NU, Wagle N. Reversion and non-reversion mechanisms of resistance (MoR) to PARP inhibitor (PARPi) or platinum chemotherapy (chemotx) in patients (pts) with BRCA1/2-mutant metastatic breast cancer (MBC). Journal of Clinical Oncology. 37: 1085-1085. DOI: 10.1200/Jco.2019.37.15_Suppl.1085 |
0.464 |
|
| 2019 |
Garrido-Castro AC, Spurr L, Hughes ME, Li YY, Cherniack AD, Bychkovsky BL, Barroso-Sousa R, Lascio SD, Files J, Kumari P, Cerami E, Krop IE, MacConaill LE, Lindeman NI, Rollins BJ, ... ... Wagle N, et al. Genomic landscape of de novo stage IV breast cancer. Journal of Clinical Oncology. 37: 1022-1022. DOI: 10.1200/Jco.2019.37.15_Suppl.1022 |
0.435 |
|
| 2019 |
Buendia-Buendia J, Cohen O, Kim D, Jain E, Winer EP, Lin NU, Wagle N. Characterization of mutational processes in ER+ metastatic breast cancer. Journal of Clinical Oncology. 37: 1019-1019. DOI: 10.1200/Jco.2019.37.15_Suppl.1019 |
0.429 |
|
| 2019 |
Jain E, Kim D, Buendia J, Cohen O, Sousa R, Anastasio E, Dunphy M, McGillicuddy M, Stoddard R, Balch S, Thomas B, Lascio SD, Tomson B, Nguyen C, Painter C, Wagle N, et al. Abstract PD9-03: The genomic landscape of de novo metastatic breast cancer (MBC) Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Pd9-03 |
0.526 |
|
| 2019 |
Cohen O, Buendia-Buendia J, Wander S, Nayar U, Mao P, Waks A, Kim D, Freeman S, Adalsteinsson V, Helvie K, Livitz D, Rosebrock D, Leshchiner I, Dellostritto L, Garrido-Castro A, ... ... Wagle N, et al. Abstract PD9-02: Evolutionary analysis of 462 serial metastatic biopsies from 208 patients with estrogen receptor-positive (ER+) metastatic breast cancer (MBC) using whole exome sequencing (WES) Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Pd9-02 |
0.507 |
|
| 2019 |
Garrido-Castro A, Hughes M, Cherniack A, Barroso-Sousa R, Bychkovsky B, Lascio SD, Berger A, Mittendorf E, Files J, Guo H, Kumari P, Cerami E, Krop I, Wagle N, Lindeman N, et al. Abstract PD9-01: Genomic alterations associated with loss of HR expression in metastatic breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Pd9-01 |
0.368 |
|
| 2019 |
Rosenbluth J, Zervantonakis I, Boedicker M, Wagle N, Dillon D, Nakhlis F, Brugge J, Overmoyer B. Abstract P5-17-01: Patient-derived organoid models of inflammatory breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P5-17-01 |
0.415 |
|
| 2019 |
Zañudo JGT, Mao P, Montero J, Xu G, Kowalski KJ, Johnson GN, Baselga J, Scaltriti M, Letai AG, Wagle N, Albert R. Abstract 675: Network modeling of drug resistance mechanisms and drug combinations in breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-675 |
0.333 |
|
| 2019 |
Mao P, Cohen O, Kowalski K, Kusiel J, Buendia J, Exman P, Wander SA, Waks AG, Winer EP, Lin NU, Wagle N. Abstract 314: Acquired FGF and FGFR alterations confer resistance to estrogen receptor (ER) targeted therapy in metastatic ER+ breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-314 |
0.385 |
|
| 2018 |
Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, Painter C, Freeman S, Persky NS, Marini L, Helvie K, Oliver N, Rozenblatt-Rosen O, Ma CX, Regev A, ... ... Wagle N, et al. Acquired HER2 mutations in ER metastatic breast cancer confer resistance to estrogen receptor-directed therapies. Nature Genetics. PMID 30531871 DOI: 10.1038/S41588-018-0287-5 |
0.707 |
|
| 2018 |
Hinohara K, Wu HJ, Vigneau S, McDonald TO, Igarashi KJ, Yamamoto KN, Madsen T, Fassl A, Egri SB, Papanastasiou M, Ding L, Peluffo G, Cohen O, Kales SC, Lal-Nag M, ... ... Wagle N, et al. KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer Cell. PMID 30472020 DOI: 10.1016/J.Ccell.2018.10.014 |
0.431 |
|
| 2018 |
Bellmunt J, Lalani AA, Jacobus S, Wankowicz SA, Polacek L, Takeda DY, Harshman LC, Wagle N, Moreno I, Lundgren K, Bossé D, Van Allen EM, Choueiri TK, Rosenberg JE. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. British Journal of Cancer. PMID 30220708 DOI: 10.1038/S41416-018-0261-0 |
0.588 |
|
| 2018 |
Kuang Y, Siddiqui B, Hu J, Pun M, Cornwell M, Buchwalter G, Hughes ME, Wagle N, Kirschmeier P, Jänne PA, Paweletz CP, Lin NU, Krop IE, Barry WT, Winer EP, et al. Unraveling the clinicopathological features driving the emergence of mutations in metastatic breast cancer. Npj Breast Cancer. 4: 22. PMID 30083595 DOI: 10.1038/s41523-018-0075-5 |
0.344 |
|
| 2018 |
Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S, Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, ... ... Wagle N, et al. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. Cancer Discovery. PMID 29903880 DOI: 10.1158/2159-8290.Cd-18-0275 |
0.636 |
|
| 2018 |
Edelman G, Rodon J, Lager J, Castell C, Jiang J, Van Allen EM, Wagle N, Lindeman NI, Sholl LM, Shapiro GI. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors. The Oncologist. PMID 29593099 DOI: 10.1634/Theoncologist.2017-0691 |
0.552 |
|
| 2018 |
Jeselsohn R, Bergholz JS, Pun M, Cornwell M, Liu W, Nardone A, Xiao T, Li W, Qiu X, Buchwalter G, Feiglin A, Abell-Hart K, Fei T, Rao P, Long H, ... ... Wagle N, et al. Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. Cancer Cell. 33: 173-186.e5. PMID 29438694 DOI: 10.1016/J.Ccell.2018.01.004 |
0.425 |
|
| 2018 |
Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, et al. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017760033. PMID 29298117 DOI: 10.1200/Jco.2017.76.0033 |
0.526 |
|
| 2018 |
Mullane SA, Painter C, Dunphy M, Anastasio E, Simoncelli T, Zarrelli K, Philippakis A, McKay RR, Choueiri TK, Golub T, Lander E, Wagle N, Van Allen EM. The Metastatic Prostate Cancer project (MPCproject): Translational genomics through direct patient engagement. Journal of Clinical Oncology. 36: 279-279. DOI: 10.1200/Jco.2018.36.6_Suppl.279 |
0.438 |
|
| 2018 |
Wagle N, Painter C, Van Allen EM, Bass AJ, Anastasio E, Dunphy M, McGillicuddy M, Stoddard R, Balch S, Thomas B, Tomson BN, Nguyen C, Jain E, Wankowicz S, Palma J, et al. Count me in: A patient-driven research initiative to accelerate cancer research. Journal of Clinical Oncology. 36: e13501-e13501. DOI: 10.1200/Jco.2018.36.15_Suppl.E13501 |
0.436 |
|
| 2018 |
Wander SA, Cohen O, Johnson GN, Kim D, Luo F, Mao P, Nayar U, Helvie K, Marini L, Freeman S, Getz G, Garraway LA, Winer EP, Lin NU, Wagle N. Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). Journal of Clinical Oncology. 36: 12016-12016. DOI: 10.1200/Jco.2018.36.15_Suppl.12016 |
0.741 |
|
| 2018 |
Barroso-Sousa R, Guo H, Barry WT, Ferreira AR, Rees R, Winer EP, Wagle N, Tolaney SM. A phase I study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): safety, tolerability and pharmacokinetic (PK) analysis. Journal of Clinical Oncology. 36: 1068-1068. DOI: 10.1200/Jco.2018.36.15_Suppl.1068 |
0.335 |
|
| 2018 |
Waks AG, Tolaney SM, Schnitt SJ, Dillon D, Gjini E, Abdelrahman S, Marino-Enriquez A, Helvie K, Marini L, Cohen O, Kim D, Wander SA, Stover DG, Rodig S, Krop IE, ... ... Wagle N, et al. The tumor-immune microenvironment (TME) in HR+/HER2- metastatic breast cancer (mBC): Relationship to non-metastatic (met) tumors and prior treatment (tx) received. Journal of Clinical Oncology. 36: 1054-1054. DOI: 10.1200/Jco.2018.36.15_Suppl.1054 |
0.413 |
|
| 2018 |
Barroso-Sousa R, Jain E, Kim D, Partridge AH, Cohen O, Wagle N. Determinants of high tumor mutational burden (TMB) and mutational signatures in breast cancer. Journal of Clinical Oncology. 36: 1010-1010. DOI: 10.1200/Jco.2018.36.15_Suppl.1010 |
0.43 |
|
| 2018 |
Mao P, Kusiel J, Cohen O, Wagle N. Abstract PD4-01: The role of FGF/FGFR axis in resistance to SERDs and CDK4/6 inhibitors in ER+ breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Pd4-01 |
0.486 |
|
| 2018 |
Dunphy M, Jain E, Anastasio E, McGillicuddy M, Stoddard R, Thomas B, Balch S, Anderka K, Larkin K, Lennon N, Chen Y, Zimmer A, Baker EO, Maiwald S, Lapan JH, ... ... Wagle N, et al. Abstract 5384: The Angiosarcoma Project: Generating the genomic landscape of an exceedingly rare cancer through a nationwide patient-driven initiative Cancer Research. 78: 5384-5384. DOI: 10.1158/1538-7445.Am2018-5384 |
0.495 |
|
| 2018 |
Wagle N, Painter C, Anastasio E, Dunphy M, McGillicuddy M, Stoddard R, Jain E, Kim D, Lascio SD, Tompson BN, Balch S, Thomas B, Kumari P, Johnson S, Holloway J, et al. Abstract 5371: The Metastatic Breast Cancer Project: Partnering with patients to accelerate progress in cancer research Cancer Research. 78: 5371-5371. DOI: 10.1158/1538-7445.Am2018-5371 |
0.471 |
|
| 2018 |
Nayar U, Cohen O, Kapstad C, Waks A, Wander SA, Painter C, Freeman S, Ram P, Persky N, Marini L, Helvie K, Oliver N, Ma CX, Winer EP, Lin NU, ... Wagle N, et al. Abstract 4952: Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to ER-directed therapies Cancer Research. 78: 4952-4952. DOI: 10.1158/1538-7445.Am2018-4952 |
0.502 |
|
| 2018 |
Mo SS, Liu D, Gray SW, Joffe S, Wagle N, Garber J, Garraway LA, Sholl L, Janne PA, Allen EMV. Abstract 3254: Dissecting genomic determinants of response to platinum-based chemotherapy in advanced NSCLC and colorectal cancer Cancer Research. 78: 3254-3254. DOI: 10.1158/1538-7445.Am2018-3254 |
0.662 |
|
| 2017 |
Sanghvi RV, Buhay CJ, Powell BC, Tsai EA, Dorschner MO, Hong CS, Lebo MS, Sasson A, Hanna DS, McGee S, Bowling KM, Cooper GM, Gray DE, Lonigro RJ, Dunford A, ... ... Wagle N, et al. Characterizing reduced coverage regions through comparison of exome and genome sequencing data across 10 centers. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 29144510 DOI: 10.1038/Gim.2017.192 |
0.565 |
|
| 2017 |
Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed SC, Rotem D, Rhoades J, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Kim J, ... ... Wagle N, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nature Communications. 8: 1324. PMID 29109393 DOI: 10.1038/S41467-017-00965-Y |
0.736 |
|
| 2017 |
Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, et al. Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Science Translational Medicine. 9. PMID 28794284 DOI: 10.1126/Scitranslmed.Aai7993 |
0.734 |
|
| 2017 |
McGraw SA, Garber J, Jänne PA, Lindeman N, Oliver N, Sholl LM, Van Allen EM, Wagle N, Garraway LA, Joffe S, Gray SW. The fuzzy world of precision medicine: deliberations of a precision medicine tumor board. Personalized Medicine. 14: 37-50. PMID 28757884 DOI: 10.2217/Pme-2016-0074 |
0.668 |
|
| 2017 |
Ladas I, Fitarelli-Kiehl M, Song C, Adalsteinsson VA, Parsons HA, Lin NU, Wagle N, Makrigiorgos GM. Multiplexed Elimination of Wild-Type DNA and High-Resolution Melting Prior to Targeted Resequencing of Liquid Biopsies. Clinical Chemistry. PMID 28679646 DOI: 10.1373/Clinchem.2017.272849 |
0.366 |
|
| 2017 |
Johnson CP, Kim IK, Esmaeli B, Amin-Mansour A, Treacy DJ, Carter SL, Hodis E, Wagle N, Seepo S, Yu X, Lane AM, Gragoudas ES, Vazquez F, Nickerson E, Cibulskis K, et al. Systematic genomic and translational efficiency studies of uveal melanoma. Plos One. 12: e0178189. PMID 28594900 DOI: 10.1371/Journal.Pone.0178189 |
0.683 |
|
| 2017 |
Ghazani AA, Oliver NM, St Pierre JP, Garofalo A, Rainville IR, Hiller E, Treacy DJ, Rojas-Rudilla V, Wood S, Bair E, Parello M, Huang F, Giannakis M, Wilson FH, Stover EH, ... ... Wagle N, et al. Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 28125075 DOI: 10.1038/Gim.2016.191 |
0.703 |
|
| 2017 |
Mullane SA, Painter C, Dunphy M, Anastasio E, Simoncelli T, Zarrelli K, Philippakis A, McKay RR, Choueiri TK, Golub T, Lander E, Wagle N, Van Allen EM. The Prostate Cancer Project (PC Project): Translational genomics through direct patient engagement. Journal of Clinical Oncology. 35: 199-199. DOI: 10.1200/Jco.2017.35.6_Suppl.199 |
0.433 |
|
| 2017 |
Painter C, Dunphy M, Anastasio E, McGillicuddy M, Anderka K, Larkin K, Lennon N, Chen Y, Lander E, Golub T, Wagle N. The Angiosarcoma Project: Generating the genomic landscape of a rare cancer through a direct-to-patient initiative. Journal of Clinical Oncology. 35: 1519-1519. DOI: 10.1200/Jco.2017.35.15_Suppl.1519 |
0.385 |
|
| 2017 |
Stover DG, Parsons HA, Ha G, Freeman S, Barry WT, Guo H, Gydush G, Reed S, Rhoades J, Rotem D, Hughes ME, Krop IE, Tolaney SM, Wagle N, Getz G, et al. Genome-wide copy number analysis of cell-free DNA from patients with chemotherapy-resistant metastatic triple-negative breast cancer. Journal of Clinical Oncology. 35: 1092-1092. DOI: 10.1200/Jco.2017.35.15_Suppl.1092 |
0.509 |
|
| 2017 |
Wagle N, Painter C, Anastasio E, Dunphy M, McGillicuddy M, Kim D, Jain E, Buendia-Buendia J, Cohen O, Knelson E, Holloway J, Johnson S, Larkin K, Adalsteinsson V, Ha G, et al. The Metastatic Breast Cancer (MBC) project: Accelerating translational research through direct patient engagement. Journal of Clinical Oncology. 35: 1076-1076. DOI: 10.1200/Jco.2017.35.15_Suppl.1076 |
0.42 |
|
| 2017 |
Luis IMVD, Guo H, Barry WT, Krop IE, Wagle N, Lowe A, Gore D, Andrews C, Osmani W, Isakoff SJ, Tung NM, Winer EP, Lin NU, Freedman RA. A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). Journal of Clinical Oncology. 35: 1034-1034. DOI: 10.1200/Jco.2017.35.15_Suppl.1034 |
0.352 |
|
| 2017 |
Tseng Y(, Hong A, Gill S, Keskula P, Raghavan S, Cheah J, Tsherniak A, Vazquez F, Alkhairy S, Peng A, Sayeed A, Deasy R, Ronning P, Kantoff P, Garraway L, ... ... Wagle N, et al. Abstract A02: Expanding tumor chemical-genetic interaction map using next-generation cancer models Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-A02 |
0.616 |
|
| 2017 |
Cohen O, Kim D, Oh C, Waks A, Oliver N, Helvie K, Marini L, Rotem A, Lloyd M, Stover D, Adalsteinsson V, Freeman S, Ha G, Cibulskis C, Anderka K, ... Wagle N, et al. Abstract S1-01: Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-S1-01 |
0.631 |
|
| 2017 |
Nayar U, Cohen O, Oh C, Wagle N. Abstract P3-04-08: The role of HER2 mutations in resistance to endocrine therapy in ER+ breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-04-08 |
0.529 |
|
| 2017 |
Mao P, Quartey Q, Cohen O, Piccioni F, Wagle N. Abstract P3-03-08: A large-scale functional screen to identify resistance mechanisms to selective estrogen receptor degraders fulvestrant and GDC-810 in ER+ breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-03-08 |
0.452 |
|
| 2017 |
Kuang Y, Siddiqui B, Hu J, Barry WT, Lin NU, Wagle N, Kirschmeier P, Jänne PA, Paweletz C, Krop I, Winer EP, Brown M, Jeselsohn R. Abstract 4950: The emergence of ESR1 mutations is associated with aromatase inhibitor and fulvestrant therapy Cancer Research. 77: 4950-4950. DOI: 10.1158/1538-7445.Am2017-4950 |
0.442 |
|
| 2017 |
Aguirre AJ, Carter S, Camarda N, Ghazani A, Nowak J, Silva AD, Brais L, Ragon D, McCabe D, Marini L, Anderka K, Helvie K, Oliver N, Babic A, Shyn P, ... ... Wagle N, et al. Abstract 3036: Real-time genomic characterization of metastatic pancreatic cancer to enable precision medicine Cancer Research. 77: 3036-3036. DOI: 10.1158/1538-7445.Am2017-3036 |
0.561 |
|
| 2017 |
Tseng Y, Hong A, Keskula P, Gill S, Cheah J, Kryukov G, Tsherniak A, Vazquez F, Cowley G, Alkhairy S, Oh C, Peng A, Deasy R, Sayeed A, Ronning P, ... ... Wagle N, et al. Abstract 1953: Accelerating prediction of pediatric and rare cancer vulnerabilities using next-generation cancer models Cancer Research. 77: 1953-1953. DOI: 10.1158/1538-7445.Am2017-1953 |
0.538 |
|
| 2016 |
Garofalo A, Sholl L, Reardon B, Taylor-Weiner A, Amin-Mansour A, Miao D, Liu D, Oliver N, MacConaill L, Ducar M, Rojas-Rudilla V, Giannakis M, Ghazani A, Gray S, Janne P, ... ... Wagle N, et al. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Medicine. 8: 79. PMID 27460824 DOI: 10.1186/S13073-016-0333-9 |
0.713 |
|
| 2016 |
Green RC, Goddard KA, Jarvik GP, Amendola LM, Appelbaum PS, Berg JS, Bernhardt BA, Biesecker LG, Biswas S, Blout CL, Bowling KM, Brothers KB, Burke W, Caga-Anan CF, Chinnaiyan AM, ... ... Wagle N, et al. Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. American Journal of Human Genetics. 99: 246. PMID 27392080 DOI: 10.1016/J.Ajhg.2016.06.002 |
0.533 |
|
| 2016 |
Green RC, Goddard KA, Jarvik GP, Amendola LM, Appelbaum PS, Berg JS, Bernhardt BA, Biesecker LG, Biswas S, Blout CL, Bowling KM, Brothers KB, Burke W, Caga-Anan CF, Chinnaiyan AM, ... ... Wagle N, et al. Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. American Journal of Human Genetics. PMID 27181682 DOI: 10.1016/J.Ajhg.2016.04.011 |
0.57 |
|
| 2016 |
Gray SW, Park ER, Najita J, Martins Y, Traeger L, Bair E, Gagne J, Garber J, Jänne PA, Lindeman N, Lowenstein C, Oliver N, Sholl L, Van Allen EM, Wagle N, et al. Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 26866579 DOI: 10.1038/Gim.2015.207 |
0.695 |
|
| 2016 |
Wagle N, Painter C, Krevalin M, Oh C, Anderka K, Larkin K, Lennon N, Dillon D, Frank E, Winer EP, Lander E, Golub T. The Metastatic Breast Cancer Project: A national direct-to-patient initiative to accelerate genomics research. Journal of Clinical Oncology. 34: LBA1519-LBA1519. DOI: 10.1200/Jco.2016.34.18_Suppl.Lba1519 |
0.49 |
|
| 2016 |
McGraw SA, Joffe S, Garber JE, Janne PA, Lindeman NI, Oliver N, Sholl LM, Allen EMV, Wagle N, Garraway LA, Gray SW. Deliberations of a precision medicine tumor board. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E13005 |
0.623 |
|
| 2016 |
Waks AG, Cohen O, Helvie K, Lloyd MR, Marini L, Oh C, Oliver N, Lindeman NI, Matulonis UA, Krop IE, Garraway LA, Winer EP, Lin NU, Wagle N. Mechanisms of resistance (MoR) to DNA damaging therapy (tx) in BRCA1/2-deficient (d) metastatic breast cancer (MBC). Journal of Clinical Oncology. 34: 542-542. DOI: 10.1200/Jco.2016.34.15_Suppl.542 |
0.623 |
|
| 2016 |
Garofalo A, Sholl LM, Reardon B, Amin-Mansour A, Miao D, Liu D, Oliver N, Ghazani AA, Gray SW, Janne PA, Garber JE, Joffe S, Lindeman NI, Garraway LA, Wagle N, et al. Performance of genomic data strategies for cancer precision medicine across distinct contexts and ethnicities. Journal of Clinical Oncology. 34: 1500-1500. DOI: 10.1200/Jco.2016.34.15_Suppl.1500 |
0.629 |
|
| 2016 |
Ghazani AA, Oliver N, Pierre JPS, Garofalo A, Sholl LM, Lindeman NI, Garber JE, Joffe S, Janne PA, Gray SW, Garraway LA, Allen EMV, Wagle N. Assigning clinical meaning to somatic and germline whole exome sequencing data to guide cancer precision medicine. Journal of Clinical Oncology. 34: 11565-11565. DOI: 10.1200/Jco.2016.34.15_Suppl.11565 |
0.648 |
|
| 2016 |
Wagle N, Helvie K, Lloyd MR, Marini L, Waks AG, Cohen O, Oh C, Sougnez C, Oliver N, Quartey Q, Rotem A, Shah P, Lindeman NI, Krop IE, Garraway LA, et al. A cancer precision medicine platform for multiple simultaneous genomic assays from metastatic biopsies (bx) in ER+ metastatic breast cancer. Journal of Clinical Oncology. 34: 11513-11513. DOI: 10.1200/Jco.2016.34.15_Suppl.11513 |
0.606 |
|
| 2016 |
Tseng Y, Keskula P, Hong AL, Gill S, Cheah JH, Kryukov GV, Tsherniak A, Vazquez F, Cowley G, Oh C, Peng A, Sayeed A, Deasy R, Ronning P, Kantoff P, ... ... Wagle N, et al. Abstract B26: Accelerating prediction of tumor vulnerabilities using next-generation cancer models Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-B26 |
0.62 |
|
| 2016 |
Formisano L, Young C, Bhola N, Bulen B, Estrada V, Wagle N, Allen EV, Brewer MR, Jansen V, Guerrero A, Giltnane J, Strcker T, Arteaga C. Abstract S3-03: Nuclear FGFR1 interaction with estrogen receptor (ER) α is associated with resistance to endocrine therapy in ER+/FGFR1-amplified breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-S3-03 |
0.314 |
|
| 2016 |
Wagle N, Painter C, Ilzarbe M, Allen EV, Frank E, Oh C, Krevalin M, Lloyd M, Anderka K, Kryukov G, Boehm J, Winer E, Lander E, Golub T. Abstract OT2-05-03: The metastatic breast cancer project: A national direct-to-patient research initiative to accelerate genomics research Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-Ot2-05-03 |
0.424 |
|
| 2016 |
Adalsteinsson VA, Ha G, Freeman S, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed S, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Cohen O, Oh C, Kim J, ... Wagle N, et al. Abstract LB-136: High concordance of whole-exome sequencing of cell-free DNA and matched biopsies enables genomic discovery in metastatic cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-136 |
0.678 |
|
| 2016 |
Tseng Y, Hong A, Keskula P, Gill S, Cheah J, Kryukov G, Tsherniak A, Vazquez F, Cowley G, Oh C, Peng A, Sayeed A, Deasy R, Ronning P, Kantoff P, ... ... Wagle N, et al. Abstract 4367: Accelerating prediction of tumor vulnerabilities using next-generation cancer models Cancer Research. 76: 4367-4367. DOI: 10.1158/1538-7445.Am2016-4367 |
0.629 |
|
| 2015 |
Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT, Duvvuri U, Bauman JE, Stransky N, Zeng Y, Gilbert BR, Pendleton KP, Wang L, Chiosea S, Sougnez C, ... Wagle N, et al. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. Jama Oncology. 1: 238-44. PMID 26181029 DOI: 10.1001/Jamaoncol.2015.34 |
0.645 |
|
| 2015 |
Kwiatkowski DJ, Wagle N. mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses? Ebiomedicine. 2: 2-4. PMID 26137524 DOI: 10.1016/J.Ebiom.2014.12.011 |
0.506 |
|
| 2015 |
Tolaney SM, Tan S, Guo H, Barry W, Van Allen E, Wagle N, Brock J, Larrabee K, Paweletz C, Ivanova E, Janne P, Overmoyer B, Wright JJ, Shapiro GI, Winer EP, et al. Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. Investigational New Drugs. PMID 26123926 DOI: 10.1007/S10637-015-0269-8 |
0.625 |
|
| 2015 |
Stover DG, Wagle N. Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments. Current Oncology Reports. 17: 15. PMID 25708799 DOI: 10.1007/S11912-015-0438-0 |
0.517 |
|
| 2015 |
Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM, Bahl S, Anderka K, et al. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discovery. 5: 358-67. PMID 25673644 DOI: 10.1158/2159-8290.Cd-14-1518 |
0.744 |
|
| 2015 |
Luis IMVD, Oh C, Wang Z, Dipiro P, Macrae EM, Painter C, Kryukov G, Krop IE, Winer EP, Lin NU, Wagle N. Whole exome sequencing (WES) in HER2+ metastatic breast cancer (MBC) patients (pts) with extraordinary responses to trastuzumab (T). Journal of Clinical Oncology. 33: 611-611. DOI: 10.1200/Jco.2015.33.15_Suppl.611 |
0.439 |
|
| 2015 |
Goetz EM, Ghandi M, Treacy D, Wagle N, Garraway LA. Abstract PR02: Identification of ERK1/2 mutations that confer resistance to MAPK pathway inhibitors Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-Pr02 |
0.592 |
|
| 2015 |
Grabiner B, Wagle N, Allen EV, Garraway L, Lorch J, Sabatini D. Abstract PR04: mTOR mutations in cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-Pr04 |
0.666 |
|
| 2015 |
Place CS, Kim IK, Esmaeli B, Amin-Mansour A, Treacy DJ, Carter SL, Hodis E, Wagle N, Seepo S, Yu X, Vazquez F, Nickerson E, Cibulskis K, McKenna A, Gabriel SB, et al. Abstract A1-15: Systematic genomic characterization of uveal melanoma Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-A1-15 |
0.621 |
|
| 2015 |
Giltnane JM, Balko JM, Stricker TL, Young C, Estrada MV, Wagle N, Allen Ev, Mu XJ, Sanchez V, Farley J, Fitzgerald K, Graber A, Pinto JA, Doimi F, Gómez H, et al. Abstract PD6-3: Recurrent ESR1 fusion transcripts are associated with endocrine resistance in estrogen receptor positive, HER2 negative breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd6-3 |
0.636 |
|
| 2015 |
Wagle N, Lin NU, Richardson AL, Leshchiner I, Mayer IA, Forero-Torres A, Hobday TJ, Dees EC, Nanda R, Rimawi MF, Guo H, Barry WT, Bose R, Shen W, Wolff AC, et al. Abstract PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003 Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd3-5 |
0.612 |
|
| 2015 |
Corcoran RB, Ahronian LG, Allen EV, Coffee EM, Wagle N, Kwak EL, Faris JE, Iafrate AJ, Garraway LA, Engelman JA. Abstract NG04: Clinical acquired resistance to RAF inhibitor combinations in BRAF mutant colorectal cancer through MAPK pathway alterations Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ng04 |
0.625 |
|
| 2014 |
Perry JA, Kiezun A, Tonzi P, Van Allen EM, Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS, Helman E, Taylor-Weiner A, McKenna A, DeLuca DS, Lawrence MS, ... ... Wagle N, et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proceedings of the National Academy of Sciences of the United States of America. 111: E5564-73. PMID 25512523 DOI: 10.1073/Pnas.1419260111 |
0.811 |
|
| 2014 |
Goetz EM, Ghandi M, Treacy DJ, Wagle N, Garraway LA. ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. Cancer Research. 74: 7079-89. PMID 25320010 DOI: 10.1158/0008-5472.Can-14-2073 |
0.57 |
|
| 2014 |
Wagle N, Grabiner BC, Van Allen EM, Amin-Mansour A, Taylor-Weiner A, Rosenberg M, Gray N, Barletta JA, Guo Y, Swanson SJ, Ruan DT, Hanna GJ, Haddad RI, Getz G, Kwiatkowski DJ, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. The New England Journal of Medicine. 371: 1426-33. PMID 25295501 DOI: 10.1056/Nejmoa1403352 |
0.726 |
|
| 2014 |
Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Kryukov GV, O'Connor KW, Sfakianos J, Garcia-Grossman I, Kim J, Guancial EA, Bambury R, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discovery. 4: 1140-53. PMID 25096233 DOI: 10.1158/2159-8290.Cd-14-0623 |
0.68 |
|
| 2014 |
Yuan Y, Van Allen EM, Omberg L, Wagle N, Amin-Mansour A, Sokolov A, Byers LA, Xu Y, Hess KR, Diao L, Han L, Huang X, Lawrence MS, Weinstein JN, Stuart JM, et al. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nature Biotechnology. 32: 644-52. PMID 24952901 DOI: 10.1038/Nbt.2940 |
0.724 |
|
| 2014 |
Cho J, Bass AJ, Lawrence MS, Cibulskis K, Cho A, Lee SN, Yamauchi M, Wagle N, Pochanard P, Kim N, Park AK, Won J, Hur HS, Greulich H, Ogino S, et al. Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Molecular Cancer. 13: 141. PMID 24894453 DOI: 10.1186/1476-4598-13-141 |
0.433 |
|
| 2014 |
Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, Jane-Valbuena J, Friedrich DC, Kryukov G, Carter SL, McKenna A, Sivachenko A, Rosenberg M, Kiezun A, Voet D, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nature Medicine. 20: 682-8. PMID 24836576 DOI: 10.1038/Nm.3559 |
0.705 |
|
| 2014 |
Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discovery. 4: 546-53. PMID 24625776 DOI: 10.1158/2159-8290.Cd-13-0353 |
0.707 |
|
| 2014 |
Van Allen EM, Foye A, Wagle N, Kim W, Carter SL, McKenna A, Simko JP, Garraway LA, Febbo PG. Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy Prostate Cancer and Prostatic Diseases. 17: 23-27. PMID 24366412 DOI: 10.1038/Pcan.2013.37 |
0.52 |
|
| 2014 |
Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, Johannessen CM, McKenna A, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discovery. 4: 61-8. PMID 24265154 DOI: 10.1158/2159-8290.Cd-13-0631 |
0.704 |
|
| 2014 |
Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, Hodis E, Rosenberg M, Mckenna A, Cibulskis K, Farlow D, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma Cancer Discovery. 4: 94-109. PMID 24265153 DOI: 10.1158/2159-8290.Cd-13-0617 |
0.717 |
|
| 2014 |
Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN, Harzstark AL, Wagle N, Figlin RA, Smith GW, Garraway LA, Choueiri T, Erlandsson F, Laber DA. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma Investigational New Drugs. 32: 178-187. PMID 24242861 DOI: 10.1007/S10637-013-0045-6 |
0.712 |
|
| 2014 |
Freedman RA, Luis IMVD, Barry WT, Krop IE, Wagle N, Lowe A, Galler S, Sohl J, Isakoff SJ, Tung NM, Winer EP, Lin NU. A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps668 |
0.389 |
|
| 2014 |
Wagle N, Lin NU, Richardson AL, Leshchiner I, Mayer IA, Forero-Torres A, Hobday TJ, Dees EC, Nanda R, Rimawi MF, Guo H, Barry WT, Wolff AC, Gabriel SB, Garraway LA, et al. Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003. Journal of Clinical Oncology. 32: 536-536. DOI: 10.1200/Jco.2014.32.15_Suppl.536 |
0.653 |
|
| 2014 |
Rosenberg JE, Van Allen EM, Mouw KW, Kim PH, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Iyer G, Signoretti S, Reuter VE, Getz G, Kantoff PW, Bochner BH, Choueiri TK, et al. Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Journal of Clinical Oncology. 32: 4510-4510. DOI: 10.1200/Jco.2014.32.15_Suppl.4510 |
0.578 |
|
| 2014 |
Gray SW, Wagle N, Garber JE, Rainville IR, Hiller E, Martins Y, Oliver N, Lowenstein C, Najita JS, VanAllen E, Janne PA, Sholl LM, Lindeman NI, Garraway LA, Joffe S. Cancer patients’ preferences for return of somatic and germline whole-exome sequencing results: Data from the CANSEQ study. Journal of Clinical Oncology. 32: 1535-1535. DOI: 10.1200/Jco.2014.32.15_Suppl.1535 |
0.573 |
|
| 2014 |
Tolaney SM, Guo H, Barry WT, Larrabee K, Brock JE, Wagle N, Allen EMV, Paweletz C, Ivanova E, Janne PA, Overmoyer B, Wright JJ, Shapiro G, Winer EP, Krop IE. A phase II study of tivantinib (ARQ-197) for metastatic triple-negative breast cancer. Journal of Clinical Oncology. 32: 1106-1106. DOI: 10.1200/Jco.2014.32.15_Suppl.1106 |
0.413 |
|
| 2014 |
Kiezun A, Perry J, Tonzi P, Allen EV, Carter SL, Baca S, Bhatt A, Lawrence M, Walensky L, Wagle N, Mora J, deTorres C, Lavarino C, Velasco-Hidalgo L, Cardenas-Cardos R, et al. Abstract A41: Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-A41 |
0.787 |
|
| 2014 |
Mu XJ, Allen EV, Wagle N, Chong C, Butaney M, Farlow D, Getz G, Jänne PA, Garraway LA. Abstract 2371: Heterogeneity of resistance mechanisms in lung adenocarcinoma patients with acquired resistance to EGFR inhibitors Cancer Research. 74: 2371-2371. DOI: 10.1158/1538-7445.Am2014-2371 |
0.632 |
|
| 2014 |
Wagle N, Grabiner BC, Allen EMV, Amin-Mansour A, Carter SC, Gray N, Barletta JA, Swanson SJ, Ruan D, Kwiatkowski DJ, Hanna GJ, Haddad RI, Sabatini D, Janne PA, Garraway LA, et al. Abstract 1724: Genomic mechanisms of exquisite sensitivity and acquired resistance to everolimus in a patient with anaplastic thyroid carcinoma Cancer Research. 74: 1724-1724. DOI: 10.1158/1538-7445.Am2014-1724 |
0.663 |
|
| 2014 |
Berg JS, Amendola LM, Eng C, Allen EV, Gray SW, Wagle N, Rehm HL, DeChene ET, Dulik MC, Hisama FM, Burke W, Spinner NB, Garraway L, Green RC, Plon S, et al. Erratum: Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the clinical sequencing exploratory research consortium (Genetics in Medicine (2013) 15 (860-867) DOI:10.1038/gim.2013.133) Genetics in Medicine. 16. DOI: 10.1038/Gim.2013.191 |
0.548 |
|
| 2014 |
Corcoran R, Coffee E, van Allen E, Ahronian L, Wagle N, Kwak E, Faris J, Iafrate A, Garraway L, Engelman J. 428 Clinical acquired resistance to combined RAF/EGFR or RAF/MEK inhibition in BRAF mutant colorectal cancer (CRC) patients through MAPK pathway alterations European Journal of Cancer. 50: 141. DOI: 10.1016/S0959-8049(14)70554-4 |
0.58 |
|
| 2014 |
Mouw K, Van Allen E, O’Connor K, Wagle N, Kim P, Al-Ahmadie H, Zhu C, Ostravnaya I, Iyer G, Signoretti S, Reuter V, Getz G, Kantoff P, Bochner B, Choueiri T, et al. Somatic ERCC2 Mutations Confer Cisplatin Sensitivity in Muscle-Invasive Urothelial Cancer International Journal of Radiation Oncology*Biology*Physics. 90: S88. DOI: 10.1016/J.Ijrobp.2014.05.481 |
0.557 |
|
| 2013 |
Berg JS, Amendola LM, Eng C, Van Allen E, Gray SW, Wagle N, Rehm HL, DeChene ET, Dulik MC, Hisama FM, Burke W, Spinner NB, Garraway L, Green RC, Plon S, et al. Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 15: 860-7. PMID 24195999 DOI: 10.1038/Gim.2013.133 |
0.675 |
|
| 2013 |
Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van Hummelen P, MacConaill LE, Shoni M, Wagle N, Jones RT, Quick CM, Laury A, Katz IT, Hahn WC, Matulonis UA, et al. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 119: 3776-83. PMID 24037752 DOI: 10.1002/Cncr.28288 |
0.42 |
|
| 2013 |
Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU. Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. Clinical Breast Cancer. 13: 254-63. PMID 23829891 DOI: 10.1016/J.Clbc.2013.02.010 |
0.39 |
|
| 2013 |
Van Allen EM, Wagle N, Levy MA. Clinical analysis and interpretation of cancer genome data. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1825-33. PMID 23589549 DOI: 10.1200/Jco.2013.48.7215 |
0.656 |
|
| 2013 |
Lane AA, Odejide O, Kopp N, Kim S, Yoda A, Erlich R, Wagle N, Abel GA, Rodig SJ, Antin JH, Weinstock DM. Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia. Leukemia. 27: 968-71. PMID 23370706 DOI: 10.1038/Leu.2013.30 |
0.366 |
|
| 2013 |
Whittaker SR, Theurillat JP, Van Allen E, Wagle N, Hsiao J, Cowley GS, Schadendorf D, Root DE, Garraway LA. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discovery. 3: 350-62. PMID 23288408 DOI: 10.1158/2159-8290.Cd-12-0470 |
0.704 |
|
| 2013 |
Wagle N, Allen EMV, Frederick DT, Cooper ZA, Farlow DN, Treacy D, Goetz EM, Johannessen CM, Carter SL, Taylor-Weiner A, Hodis E, Lawrence DP, Sullivan RJ, Getz G, Gabriel SB, et al. Whole exome and whole transcriptome sequencing in melanoma patients to identify mechanisms of resistance to combined RAF/MEK inhibition. Journal of Clinical Oncology. 31: 9015-9015. DOI: 10.1200/Jco.2013.31.15_Suppl.9015 |
0.579 |
|
| 2013 |
Lorch JH, Busaidy N, Ruan DT, Janne PA, Limaye SA, Wirth LJ, Barletta JA, Rabinowits G, Garraway LA, Allen EMV, Wagle N, Hanna GJ, Misiukiewicz K, Suda M, Haddad TC, et al. A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC). Journal of Clinical Oncology. 31: 6023-6023. DOI: 10.1200/Jco.2013.31.15_Suppl.6023 |
0.494 |
|
| 2013 |
Rollins BJ, MacConaill LE, Wagle N, Garcia E, Kuo FC, Longtine JA, Garber JE, Janeway KA, Fuchs CS, Bertagnolli MM, Soiffer R, Matulonis U, Lin NU, Hahn WC, Garraway LA, et al. PROFILE: Broadly based genomic testing for all patients at a major cancer center. Journal of Clinical Oncology. 31: 1531-1531. DOI: 10.1200/Jco.2013.31.15_Suppl.1531 |
0.616 |
|
| 2013 |
Allen EMV, Wagle N, Carter SL, Sucker A, Farlow DN, Hodis E, Taylor-Weiner A, Berking C, Egberts F, Hassel JC, Gogas H, Gutzmer R, Goldinger SM, Loquai C, Ugurel S, et al. The genetic landscape of clinical resistance to RAF inhibition in melanoma. Journal of Clinical Oncology. 31: 11009-11009. DOI: 10.1200/Jco.2013.31.15_Suppl.11009 |
0.616 |
|
| 2013 |
Rodon J, Juric D, Gonzalez-Angulo A, Bendell J, Berlin J, Bootle D, Gravelin K, Huang A, Derti A, Lehar J, Würthner J, Boehm M, Allen Ev, Wagle N, Garraway LA, et al. Abstract LB-65: Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-65 |
0.661 |
|
| 2013 |
Hummelen PV, Ducar M, Jones RT, Raza A, Sunkavalli A, Hanna M, Mills A, Adusumilli R, Kumar P, Schubert L, Breneiser M, Cooley AC, Garcia E, Scholl LM, Lindeman NI, ... Wagle N, et al. Abstract 819: Targeted sequencing to detect somatic mutations, translocations and copy-number variation in human tumors simultaneously. Cancer Research. 73: 819-819. DOI: 10.1158/1538-7445.Am2013-819 |
0.656 |
|
| 2013 |
Wagle N, Allen EV, Perrin D, Friedrich D, Fisher S, Kryukov G, Ambrogio L, Auclair D, Gray S, Joffe S, Janne P, Garber J, Macconaill L, Lindeman N, Rollins B, et al. Abstract 3152: CanSeq: prospective clinical whole-exome sequencing of FFPE tumor samples. Cancer Research. 73: 3152-3152. DOI: 10.1158/1538-7445.Am2013-3152 |
0.652 |
|
| 2013 |
Allen EMV, Wagle N, Keizun A, Kryukov G, McKenna A, Huang F, Hiller E, Rainville I, Auclair D, Ambrogio L, Gray S, Joffe S, Getz G, Garber J, Garraway L. Abstract 2570: An integrated germline analysis platform for comprehensive clinical cancer genomics. Cancer Research. 73: 2570-2570. DOI: 10.1158/1538-7445.Am2013-2570 |
0.634 |
|
| 2012 |
Balko JM, Mayer IA, Sanders ME, Miller TW, Kuba MG, Meszoely IM, Wagle N, Garraway LA, Arteaga CL. Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification. Molecular Cancer Therapeutics. 11: 2301-5. PMID 22879364 DOI: 10.1158/1535-7163.Mct-12-0511 |
0.643 |
|
| 2012 |
Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, ... ... Wagle N, et al. A landscape of driver mutations in melanoma. Cell. 150: 251-63. PMID 22817889 DOI: 10.1016/J.Cell.2012.06.024 |
0.563 |
|
| 2012 |
Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E, Ghosh P, Zhang H, Zeid R, Ren X, Cibulskis K, Sivachenko AY, ... Wagle N, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 485: 502-6. PMID 22622578 DOI: 10.1038/Nature11071 |
0.607 |
|
| 2012 |
Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, Ducar M, Van Hummelen P, Macconaill LE, Hahn WC, Meyerson M, Gabriel SB, Garraway LA. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discovery. 2: 82-93. PMID 22585170 DOI: 10.1158/2159-8290.CD-11-0184 |
0.615 |
|
| 2012 |
Wright AA, Hirsch MS, Wagle N, Howitt BE, Palescandolo E, MacConaill LE, Hummelen PV, Shoni M, Hahn WC, Matulonis UA. KRAS and EGFR mutations to distinguish adenocarcinomas and squamous cell carcinomas of the cervix. Journal of Clinical Oncology. 30: 5011-5011. DOI: 10.1200/Jco.2012.30.15_Suppl.5011 |
0.476 |
|
| 2012 |
Allen EMV, Wagle N, Kryukov G, Ramos A, Getz G, Garraway LA. A heuristic platform for clinical interpretation of cancer genome sequencing data. Journal of Clinical Oncology. 30: 10502-10502. DOI: 10.1200/Jco.2012.30.15_Suppl.10502 |
0.604 |
|
| 2012 |
Whittaker S, Hodis E, Wagle N, Hsiao J, Cowley G, Root D, Garraway L. Abstract B20: A genome-scale RNA interference screen for resistance mechanisms to BRAF inhibition in melanoma Clinical Cancer Research. 18. DOI: 10.1158/1078-0432.Mechres-B20 |
0.596 |
|
| 2012 |
Vaz-Luis I, Seah D, Olson E, Metzger O, Wagle N, Sohl J, Litsas G, Burstein H, Krop I, Winer E, Lin N. Abstract P5-18-03: Clinicopathological features among patients with HER2-positive breast cancer with prolonged response to trastuzumab based therapy Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P5-18-03 |
0.376 |
|
| 2011 |
Wagle N, Berger MF, Davis MJ, Blumenstiel B, DeFelice M, Hahn WC, Meyerson M, Gabriel SB, MacConaill LE, Garraway LA. Tumor genomic profiling of FFPE samples by massively parallel sequencing. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10502. PMID 28022364 DOI: 10.1200/Jco.2011.29.15_Suppl.10502 |
0.587 |
|
| 2011 |
Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3085-96. PMID 21383288 DOI: 10.1200/Jco.2010.33.2312 |
0.65 |
|
| 2011 |
Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA. Abstract 3933: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling Cancer Research. 71: 3933-3933. DOI: 10.1158/1538-7445.Am2011-3933 |
0.667 |
|
| 2011 |
Miller T, Fox E, Balko J, Meszoely I, Sanders M, Kuba M, Wagle N, Garraway L, Maira S, Arteaga C. S3-4: ER Downregulation with Fulvestrant in Combination with pan-PI3K Inhibitor BKM120 Synergizes Against ER+/PI3K-Mutant Breast Cancer Xenografts In Vivo. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-S3-4 |
0.628 |
|
| 2010 |
Ross JS, Torres-Mora J, Wagle N, Jennings TA, Jones DM. Biomarker-based prediction of response to therapy for colorectal cancer: current perspective. American Journal of Clinical Pathology. 134: 478-90. PMID 20716806 DOI: 10.1309/Ajcp2Y8Ktdpoaorh |
0.365 |
|
| 2010 |
Wagle N, Davis M, Berger MF, Blumenstiel B, Defelice M, Hahn W, Meyerson M, Gabriel SB, MacConaill L, Garraway LA. Abstract LB-122: High-throughput tumor genomic profiling by massively parallel sequencing Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-122 |
0.657 |
|
| 2003 |
Vaziri C, Saxena S, Jeon Y, Lee C, Murata K, Machida Y, Wagle N, Hwang DS, Dutta A. A p53-dependent checkpoint pathway prevents rereplication. Molecular Cell. 11: 997-1008. PMID 12718885 DOI: 10.1016/S1097-2765(03)00099-6 |
0.329 |
|
| 2001 |
Goldman DP, Schoenbaum ML, Potosky AL, Weeks JC, Berry SH, Escarce JJ, Weidmer BA, Kilgore ML, Wagle N, Adams JL, Figlin RA, Lewis JH, Cohen J, Kaplan R, McCabe M. Measuring the incremental cost of clinical cancer research Journal of Clinical Oncology. 19: 105-110. PMID 11134202 DOI: 10.1200/Jco.2001.19.1.105 |
0.328 |
|
| 2001 |
Schoenbaum M, Kilgore ML, Weidmer BA, Berry SH, Escarce JJ, Goldman DP, Lewis JH, Wagle N. Using hospital tumor registries to identify research subjects Health Services and Outcomes Research Methodology. 2: 67-76. DOI: 10.1023/A:1011432302562 |
0.414 |
|
| Show low-probability matches. |